Ovarian function in female survivors of high‐risk neuroblastoma

Abstract

AbstractIntroductionData on ovarian function in neuroblastoma survivors are limited. We sought to determine the prevalence of ovarian dysfunction in a cohort of high‐risk neuroblastoma survivors and compare outcomes among survivors treated with and without autologous stem cell rescue (ASCR) preceded by myeloablative chemotherapy.MethodsRetrospective review of female survivors of high‐risk neuroblastoma ≥5 years from diagnosis, diagnosed between 1982 and 2014, and followed in a tertiary cancer center. Participants were divided into two groups: individuals treated with conventional chemotherapy ± radiation (“non‐ASCR”) (n = 32) or with chemotherapy ± radiation followed by myeloablative chemotherapy with ASCR (“ASCR”) (n = 51). Ovarian dysfunction was defined as follicle‐stimulating hormone ≥15 mU/mL, while premature ovarian insufficiency (POI) was defined as persistent ovarian dysfunction requiring hormone replacement therapy. Poisson models were used to determine prevalence ratios of ovarian dysfunction and POI.ResultsAmong 83 females (median attained age: 19 years [range, 10‐36]; median follow‐up: 15 years [range, 7‐36]), 49 (59%) had ovarian dysfunction, and 34 (41%) developed POI. Survivors treated with ASCR were 3.2‐fold more likely to develop ovarian dysfunction (95% CI: 1.8‐6.0; p < 0.001) and 4.5‐fold more likely to develop POI (95% CI: 1.7‐11.7; p = 0.002) when compared with those treated with conventional chemotherapy, after adjusting for attained age. Two participants in the non‐ASCR group and six in the ASCR group achieved at least one spontaneous pregnancy.DiscussionOvarian dysfunction is prevalent in female high‐risk neuroblastoma survivors, especially after ASCR. Longitudinal follow‐up of larger cohorts is needed to inform counseling about the risk of impaired ovarian function after neuroblastoma therapy.